Objective-Dual-antiplatelet therapy with acetylsalicylic acid and a P2Y 12 antagonist, such as clopidogrel, is the standard of care for acute coronary syndromes. However, the drugs have divergent effects on the formation of cAMP, an inhibitory second messenger. Thus, by inhibiting the synthesis of prostacyclin, acetylsalicylic acid reduces cAMP formation, whereas clopidogrel potentiates it. Therefore, with higher doses of acetylsalicylic acid, the potentiation of cAMP production by clopidogrel may be attenuated, which could limit the antithrombotic potential of the drug combination. The purpose of this study was to examine this possibility in vivo. Approach and Results-Mice were given oral acetylsalicylic acid at varying doses, oral clopidogrel (5 mg/kg body weight), or both. At doses of 0.15 and 0.6 mg/kg, acetylsalicylic acid inhibited arachidonic acid-induced platelet aggregation, but only 0.6 mg/kg acetylsalicylic acid, or higher, decreased the plasma levels of 6-keto-prostaglandin-F 1α , the stable metabolite of prostacyclin. When given with clopidogrel, laser injury-induced arterial thrombi were significantly larger with the 0.6 mg/kg dose of acetylsalicylic acid than with the 0.15 mg/kg dose. Thrombi in mice treated with clopidogrel and the 0.15 mg/kg dose of acetylsalicylic acid were smaller than in mice treated with clopidogrel alone, suggesting that acetylsalicylic acid can add to the antithrombotic effect of clopidogrel but that higher doses of acetylsalicylic acid blunt the antithrombotic effect of clopidogrel. 
A rterial thrombosis, which is the underlying cause of most heart attacks and strokes, is the leading cause of morbidity and mortality worldwide. 1 Platelets are central to the pathogenesis of arterial thrombosis and are a major component of arterial thrombi that form at sites of atherosclerotic plaque disruption. Platelets activated at these sites recruit additional platelets by releasing stored ADP and by synthesizing and releasing thromboxane A 2 (TXA 2 ). Released ADP and TXA 2 promote platelet aggregation by binding to their receptors: P2Y 1 and P2Y 12 and the thromboxane receptor, respectively. 2 Drugs that antagonize P2Y 12 , such as clopidogrel, prasugrel, and ticagrelor or inhibit TXA 2 synthesis, such as acetylsalicylic acid (ASA), have antithrombotic effects. In patients with acute coronary syndromes or in those that undergo percutaneous coronary interventions with stent placement, dual-antiplatelet therapy (DAPT) with ASA and a P2Y 12 antagonist is the standard of care. 3 Although ASA has been used for prevention and treatment of arterial thrombosis for many years, the dose has changed.
Whereas daily doses of 325 mg or higher were commonly used in the past, 4 current guidelines recommend daily doses of 75 to 100 mg. 3, 5 ASA not only inhibits TXA 2 synthesis by irreversibly inactivating platelet cyclooxygenase-1 but also has the potential to reduce the synthesis of prostacyclin (PGI 2 ) by inhibiting cyclooxygenase in endothelial cells; an effect that is dose-dependent. [6] [7] [8] [9] [10] [11] [12] Reduced PGI 2 synthesis with ASA is problematic because by activating adenylate cyclase (AC) to produce cAMP, PGI 2 not only promotes vasodilation but also inhibits platelet aggregation. 13 Platelets express 2 G protein-coupled receptors for ADP. P2Y 1 leads to platelet shape change and reversible aggregation. P2Y 12 signaling reinforces ADP-induced platelet aggregation, stabilizes platelet aggregates, and amplifies platelet degranulation induced by strong agonists.
14 In addition, P2Y 12 signaling inhibits AC through Gi (a G protein isoform).
14 Although inhibition of AC by P2Y 12 signaling has no causal relationship with ADP-induced platelet activation/aggregation in vitro, it may contribute to thrombus formation in vivo by counteracting the inhibitory effects of endogenous PGI 2 or other substances that stimulate AC. Thus, it has been shown that PGI 2 inhibits platelet aggregation induced by high concentrations of thrombin only in the presence of an antagonist of P2Y 12 because it counteracts the inhibitory effect of secreted ADP on AC. 15 Based on this finding, it was hypothesized that potentiation of the antiplatelet effect of PGI 2 in vivo may contribute to the antithrombotic effect of P2Y 12 inhibition, which could be blunted by the coadministration of ASA at doses that interfere with the production of PGI 2 .
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In this study, to determine the impact of PGI 2 levels on the in vivo antithrombotic effect of DAPT in a mouse arterial thrombosis model, we (1) evaluated the effects of different doses of ASA on PGI 2 formation, and (2) compared the effect of doses of ASA that did or did not reduce PGI 2 formation, in combination with clopidogrel on thrombus formation. The interplay of ASA dosing on the antithrombotic effect of P2Y 12 antagonists has not been evaluated in either preclinical or clinical studies.
Materials and Methods
Data available on request from the authors. Please see the Major Resources Table in the online-only Data Supplement.
Preparation of ASA and Clopidogrel Suspensions
With the aid of a sonicator, ASA crystals (A2093, Sigma) were dissolved in distilled water and clopidogrel tablets (Plavix, Sanofi) were dissolved in diluted apple jelly. Both solutions were made fresh daily and given to mice within an hour of preparation.
Oral Delivery of ASA and Clopidogrel
Age-matched C57BL/6J male mice (000664; Jackson Laboratories) weighing at least 25 g were used at 8 to 12 weeks of age. Anesthesia was initiated with an intraperitoneal injection of 125 mg/kg of ketamine (02173239; Wyeth Animal Health), 12.5 mg/kg of xylazine (02169592; Bayer), and 0.25 mg/kg of atropine (00238481; Rafter 8) and maintained with Nembutal (86665/04; Ceva Sante Animal). All mice received 100 μL of vehicle or an equal volume of ASA, clopidogrel or both by gavage using 20-gauge animal feeding needles (7910; Popper and Sons, Inc). ASA was given only once, 4 hours before study, whereas clopidogrel was given twice: 24 and 4 hours before study. ASA and clopidogrel were given at doses up to 5 mg/kg body weight.
Blood samples were collected via carotid artery cannulation into 3.2% sodium citrate (366415; Becton Dickinson) at a ratio of 9:1 (vol:vol). 16 Studies were done according to the Canadian Council of Animal Care Guidelines, and all animal use protocols were approved by the Animal Research Ethics Board at McMaster University.
Effect of ASA on Plasma 6-KetoProstaglandin F 1α levels Platelet-free plasma was obtained from blood by twice subjecting it to centrifugation at 3000g for 5 minutes at room temperature. All samples were stored in the presence of 10 μg/mL indomethacin (I7378; Sigma) at −80°C. Plasma levels of 6-Keto-Prostaglandin F 1α (6-keto-PGF 1α ), the stable metabolite of PGI 2 , were quantified using a competitive ELISA (515211; Cayman Chemical) with a lower limit of detection of 1.6 pg/mL.
Platelet Aggregation Studies
Aliquots of whole blood (175 μL) were mixed with an equal volume of normal saline containing 3 mmol/L CaCl 2 in the cup of a pediatric Multiplate test cell (MP0028; Diapharma) before incubation for 3 minutes at 37°C. To determine the antiplatelet effects of ASA and clopidogrel, 25 μmol/L arachidonic acid (MP0210; Diapharma) or 10 μmol/L ADP (A2754; Sigma) was added and electric impedance was recorded at 0.5 s intervals for 6 minutes using a Multiplate Analyzer (MP0010; Diapharma) and area under the curve was determined. 16 In some experiments, aggregation was initiated with 0.8 U/mL bovine thrombin (T7513; Sigma) in the absence or presence of 15 μmol/L PGI 2 (538925; Millipore Calbiochem).
Determination of Platelet cAMP Levels
Mice were given vehicle or 5 mg/kg clopidogrel. Blood was collected into heparin (00727520; Leo Pharma, Inc) and platelets were isolated as previously described 16 in the absence of added PGI 2 . After adjusting the platelet count to 1×10 8 /mL with Tyrode buffer (134 mmol/L NaCl, 0.34 mmol/L Na 2 HPO 4 , 2.9 mmol/L KCl, 12 mmol/L NaHCO 3 , 20 mmol/L HEPES, pH 7.0, containing 5 mmol/L glucose and 0.35% BSA), 0.8 U/ mL bovine thrombin alone or in combination with 15 μmol/L PGI 2 was added to 500-μL aliquots of platelet suspension and incubated at room temperature for 2 minutes in the presence of 1 mmol/L CaCl 2 . To each sample, 2.5% trichloroacetic acid was added, and samples were then snap-frozen in liquid nitrogen. Samples were later thawed and shaken at 4°C for 45 minutes. Protein precipitates were excluded from the samples by centrifugation at 4°C for 30 minutes. Trichloroacetic acid in the supernatant was extracted 3× by mixing with 5 volumes of water-saturated ether. Residual ether was then removed by heating the samples at 70°C for 10 minutes. All samples were stored at −80°C before cAMP quantification using a competitive ELISA (581001; Cayman Chemical).
Intravital Analysis of Thrombus Formation After Laser-Induced Injury to Cremaster Muscle Arterioles
Intravital microscopy (Intelligent Imaging Innovations) was performed 24 to 25 hours after the first gavage. The cremaster muscle was prepared as previously described. 16 Using a jugular vein cannulus, mice were given 0.1 μg/g Dylight-649-tagged anti-GPIbβ (glycoprotein Iβ subunit) antibody (X649; Emfret Analytics). Multiple arterial thrombi were induced by laser injury and monitored for 220 s, and fluorescence data were analyzed as previously described.
16,17

Statistical Analyses
For normally distributed data, means±SEM were determined, and 2-tailed Student t tests and 1-way or 2-way ANOVAs were used to compare means. After ANOVAs, Tukey or Bonferroni multiple comparison tests were performed. When data failed the test for normality (Shapiro-Wilk, Prism), medians and interquartile ranges were determined, and Kruskal-Wallis test with Dunn multiple comparison test was performed on selected groups. In select situations, a MannWhitney test was performed to obtain a P value. For all analyses, P values <0.05 were considered statistically significant.
Results
ASA at 0.6 mg/kg, but not at 0.15 mg/kg, Reduces Circulating 6-keto-PGF 1α Levels Plasma levels of 6-keto-PGF 1α were measured 4 hours after ASA administration (Figure 1 ). At 0.15 mg/kg, ASA had no effect on circulating 6-keto-PGF 1α levels. In contrast, ASA doses at 0.6 or 5 mg/kg maximally inhibited PGI 2 production producing ≈50% reduction in circulating 6-keto-PGF 1α levels ( Figure 1 ). 
ASA Inhibits Arachidonic Acid-Induced Platelet Aggregation In Vitro
Platelet aggregation induced by arachidonic acid was significantly suppressed with ASA doses as low as 0.15 mg/kg, and the inhibitory effect of this dose was similar to those of 0.3 and 0.6 mg/kg ASA doses ( Figure 2 ).
Clopidogrel at 5 mg/kg Maximally Inhibits ADP-Induced Platelet Aggregation In Vitro
Clopidogrel attenuated ADP-induced platelet aggregation in a dose-dependent manner. Clopidogrel doses of 1.25, 2.5, and 3.75 mg/kg partially inhibited ADP-induced platelet aggregation, whereas a dose of 5 mg/kg (or higher; data not shown) almost completely inhibited ADP-induced platelet aggregation ( Figure 3 ).
Clopidogrel Potentiates the Antiplatelet Effect of PGI 2 In Vitro
Although a clopidogrel dose of 5 mg/kg maximally inhibited ADP-induced platelet aggregation, it had no effect on platelet aggregation induced by 0.8 U/mL thrombin. Whereas PGI 2 (15 μmol/L) had no effect on thrombin-induced aggregation of platelets from vehicle-treated mice, it significantly inhibited thrombin-induced aggregation of platelets from mice given clopidogrel (Figure 4 ). This likely reflects loss of the inhibitory effect of released ADP on AC because PGI 2 increased the levels of cAMP in thrombin-stimulated platelets from mice given clopidogrel but not in thrombin-stimulated platelets from vehicle-treated mice ( Figure 5 ). Thus, PGI 2 only promotes platelet cAMP formation and inhibits highdose thrombin-induced platelet aggregation in the presence of clopidogrel, a finding in keeping with a similar observation in human platelets treated with cangrelor, a P2Y 12 antagonist. PGI 2 formation, whereas the 0.15 mg/kg dose did not. To explore the influence of PGI 2 inhibition on the antithrombotic effects of clopidogrel, we compared in vivo thrombus formation in mice treated with clopidogrel alone or with clopidogrel in combination with ASA at either the 0.15 or 0.6 mg/kg dose. On its own, clopidogrel significantly inhibited thrombus formation compared with vehicle ( Figure 6 ). When clopidogrel was given in combination with 0.6 mg/kg ASA, thrombi were significantly larger than those measured with clopidogrel alone (Figure 6 ). In contrast, when clopidogrel was given in combination with 0.15 mg/kg ASA (Figure 6 ), thrombi were significantly smaller than those in mice treated with clopidogrel and 0.6 mg/kg ASA, and smaller (significant for the maximal thrombus volume and P=0.09 for the 10-timepoint sum Figure 5 . Effect of clopidogrel and prostacyclin (PGI 2 ) on platelet cAMP levels. Heparinized whole blood was obtained from mice between fourth and fifth h after the last oral administration of vehicle or clopidogrel (5 mg/ kg body weight), and platelets were then washed and suspended in Tyrode buffer. cAMP levels in resting platelets, in 0.8 U/mL thrombin-activated platelets, and in 0.8 U/mL thrombin-activated platelets in the presence of 15 μmol/L PGI 2 , were determined using a competitive ELISA. Means±SEM are shown (N=4). Two-way ANOVA followed by Bonferroni multiple comparison tests, ***P<0.0001. of thrombus volume) than those in mice given clopidogrel alone ( Figure 6A and 6B) . Therefore, when PGI 2 formation is inhibited by higher doses of ASA the in vivo antithrombotic effect of clopidogrel is attenuated, but at lower doses, ASA adds to the in vivo antithrombotic effect of clopidogrel.
Discussion
In this study, we provide in vivo evidence that ASA only potentiates the antithrombotic effect of clopidogrel when it is given at doses that do not impair PGI 2 formation. If administered in doses that reduce PGI 2 formation, ASA attenuates the antithrombotic effect of clopidogrel (Figures 1 and 6) . Mechanistically, our study with mouse platelets confirms the finding with human platelets that by releasing the inhibitory effect of ADP on AC, P2Y 12 antagonism is essential for PGI 2 to exert its cAMP-mediated inhibitory effect on thrombininduced platelet aggregation (Figures 4 and 5) . 15 Most importantly, our study supports the hypothesis that doses of ASA that inhibit PGI 2 production can blunt the antithrombotic effects of P2Y 12 antagonists. 15 There is a consensus on the dosage of P2Y 12 antagonists but not on ASA dosing. 18, 19 Recent analyses of data from the PLATO trial (Platelet Inhibition and Patient Outcomes) revealed geographic differences in the dose of ASA used in conjunction with ticagrelor. Higher ASA doses were used in North America than in Europe, and this difference was postulated to be a potential explanation for the observation that patients enrolled in North America derived less benefit from ticagrelor over clopidogrel than those enrolled in other countries. 15, 20 The findings of this study provide a potential mechanistic basis for the difference in benefit.
The potential for ASA to attenuate the antithrombotic effect of P2Y 12 antagonists raises the question as to whether ASA should be added to them. Clopidogrel was marginally more effective than ASA in the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events). 21 The superiority of DAPT over ASA monotherapy in acute coronary syndromes was established in the CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events). 18 In contrast, studies comparing the efficacy of DAPT versus P2Y 12 antagonist monotherapy in acute coronary syndromes are lacking. An ongoing trial which is comparing the effectiveness of extended ticagrelor monotherapy versus DAPT in acute coronary syndromes may provide further insights (URL: http:// www.clinicaltrials.gov. Unique identifier: NCT01813435).
Our finding that at 0.15 mg/kg, ASA inhibits TXA 2 formation, as evidenced by decreased arachidonic acid-induced platelet aggregation, without altering PGI 2 formation, as evidenced by preserved 6-keto-PGF 1α (Figures 1 and 2) , and added antithrombotic potency to clopidogrel monotherapy suggests that, at least in mice, ASA can add to the benefit of clopidogrel. In vitro studies did show that the combination of ASA and clopidogrel is more effective in inhibiting human platelet aggregation. 22 The doses of ASA that preserve PGI 2 formation in humans are unknown and vary between subjects 8, 11, 23 and with disease. 8, [24] [25] [26] Earlier studies suggested that 81 mg of ASA does not completely preserve PGI 2 formation. 9, 11, 23, 26 In patients with transient ischemic attacks, an ASA dose of 30 mg once daily was as effective as a higher dose at preventing recurrent ischemia. 27 In patients with acute coronary syndromes, an ASA daily dose of 75 mg was highly effective in preventing myocardial infarction and death; 28 the clinical efficacy of lower doses of ASA has not been tested in acute coronary syndromes. It is noteworthy that dipyridamole, a platelet inhibitor that partly works by increasing PGI 2 production, 29 in combination with low dose ASA at 25 mg twice daily (Aggrenox) 30 or at 75 mg daily (average dose of different ASA regimens) 31 reduced stroke recurrences more efficiently than ASA monotherapy. In contrast, dipyridamole in combination with higher doses of ASA (150-1,300 mg daily), was not superior to ASA monotherapy in previous studies. 31 Preclinical studies of experimental thrombosis also showed greater antithrombotic efficacy of dipyridamole when combined to low dose ASA than with high-dose ASA. 32 Future studies should explore whether the current low dose of ASA of 81 mg 3, 5 inhibits the formation of PGI 2 in humans and, if it does, whether a lower dose of ASA would preserve PGI 2 formation, while still inhibiting the platelet production of TXA 2 over 95%.
Of note, a formulation of 75 mg controlled-release ASA provided a similar reduction on serum TXA 2 levels as immediate-release ASA at dosing of ≥75 mg in normal humans. However, only the controlled-release ASA preserved PGI 2 biosynthesis. 33 In addition, a study on patients with type 2 diabetes mellitus also showed that an extended-release ASA formulation maintained platelet inhibition with no effect on PGI 2 formation. 34 Future studies should also explore the antithrombotic potency of the coadministration of a P2Y 12 antagonist with a controlled-release ASA. Such evidence would justify the clinical study of DAPT with an optimal dosing or formulation of ASA, with the goal of promoting the profound synergistic platelet inhibition we describe. Our study also suggests that PGI 2 suppressing nonsteroidal anti-inflammatory drugs might blunt the efficacy of P2Y 12 inhibitors.
ASA has been shown to inhibit platelet activation independently of platelet cyclooxygenase-1, 35, 36 this occurs more with doses >81 mg. ASA can also upregulate genes that are important in platelet function. 37, 38 Thus 1 limitation of our study is that although we chose our ASA dosing based on the effect on cyclooxygenase, we did not evaluate measures of these cyclooxygenase-independent effects.
In conclusion, our study highlights the importance of preclinical evaluation of drug combinations. Our findings support the hypothesis that reduced PGI 2 formation from coadministration of ASA may blunt the overall efficacy of P2Y 12 inhibition. 15, 20 Our demonstration that a PGI 2 -sparing ASA dose also inhibited TXA 2 -mediated platelet activation and reduced thrombus volume, suggests that optimizing the dosing of ASA so as to preserve PGI 2 formation will maximize the antithrombotic effect of DAPT.
